Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga, José; Semiglazov, Vladimir; van Dam, Peter; Manikhas, Alexey; Bellet, Meritxell; Mayordomo, José; Campone, Mario; Kubista, Ernst; Greil, Richard; Bianchi, Giulia; Steinseifer, Jutta; Molloy, Betty; Tokaji, Erika; Gardner, Humphrey; Phillips, Penny; Stumm, Michael; A Lane, Heidi; Michael Dixon, J; Jonat, Walter; S Rugo, Hope

doi:10.1200/jco.2008.18.8391

Public

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Jun 1, 2009

NobleIDark:/48914/w1/20260526/35CCE96FRecord on NobleID

Authors:

José Baselga

,

Vladimir Semiglazov

,

Peter van Dam

Abstract

PURPOSE: Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism of resistance to endocrine therapy, and blockade of both pathways enhances antitumor activity in preclinical models. This study explored wh...

Discussions